Navigation Links
PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
Date:9/22/2007

PARSIPPANY, N.J., Sept. 19 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to PREOS(R) (parathyroid hormone [rDNA origin] for injection) for the treatment of hypoparathyroidism, a rare deficiency of parathyroid hormone for which there is no FDA-approved therapy.

Hypoparathyroidism afflicts approximately 65,000 people in the United States and an estimated 120,000 outside of the U.S. It is most often caused by injury to or removal of the parathyroid glands during neck surgery. It also occurs as an autoimmune disorder associated with HIV infection. Current treatments include vitamin D analogs and large doses of supplemental calcium to relieve the symptoms of neuromuscular irritability associated with hypoparathyroidism. Despite these palliative therapies, the absence of endogenous parathyroid hormone compromises the body's ability to properly absorb calcium. This invariably results in hypercalciuria and nephrocalcinosis, a serious condition characterized by calcium deposition in the kidneys. PREOS could potentially be a first-in-class therapy for use in this condition.

"We greatly appreciate the FDA's support of our efforts to evaluate the use of PREOS as a hormone replacement therapy to treat hypoparathyroidism. The results of the proof-of-concept study using PREOS in this indication have been very encouraging, especially when compared to current palliative therapies that often result in long-term toxicities and complications for patients. We are excited to expand the development of PREOS beyond our initial focus on osteoporosis to include the drug's potential use as a treatment for hypoparathyroidism," said Dr. Francois Nader, executive vice president and chief operating officer of NPS.

Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 Americans annually. Orphan drug designation entitles NPS to a seven-year period of marketing exclusivity in the United States for PREOS, if it is approved by the FDA for the treatment of hypoparathyroidism, and enables the company to apply for research funding, tax credits for certain research expenses, and a waiver from the FDA's application user fee.

About NPS

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.

About PREOS

PREOS is recombinant human parathyroid hormone (PTH). NPS has studied PREOS in a number of clinical settings to document its safety and effects on bone. The pivotal Phase 3 study, known as TOP (Treatment of Osteoporosis with PTH), was a multi-center, randomized, double-blind and placebo-controlled clinical trial designed to evaluate the potential of PTH to reduce the risk of first and subsequent vertebral fractures in post-menopausal women.

In the TOP study, PREOS demonstrated a statistically significant reduction in the risk of new vertebral fractures in women with and without pre-existing osteoporosis-related fractures. Results from the TOP study have been the foundation of both the E.U. and the U.S. marketing authorization applications.

PREOS has been approved in Europe under the brand name Preotact and is being marketed by Nycomed.

Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of September 19, 2007 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2007.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian Doctor granted US patent on organ regeneration
2. Bail Granted To The Doctor Despite Her Patients Death
3. Azerbaijan Granted 5 million dollars in Fight Against Bird Flu
4. Developer Of Vaccine For Cancer Granted A Prestigious Fellowship
5. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
6. American Senior Citizens Granted More Time
7. Numerous Defense Personnel Granted Early Retirement Due to Mental Illness
8. Man Accused of Spreading HIV Granted Bail in Australia
9. The AIDS Pandemic May Orphan 18 Million African Children By 2010
10. Child Health: Orphanage vs. Foster Care, A Study
11. Ker Govt To Adopt Orphaned Kids Of HIV Infected Parents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... On January ... family scheduled an appointment after they noticed their furnace not producing any heat. Shortly ... heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide into ...
(Date:2/9/2016)... ... ... METTLER TOLEDO has published a new guide entitled “Essential ... the techniques they use so they can more easily spot potential error sources ... to create a leaner overall lab experience. , The new guide offers ...
(Date:2/9/2016)... ... ... i2i Systems, an early innovator and developer of population health management technology, ... report, Population Health Management 2015: How Far Can Your Vendor Take You? , ... The latest KLAS Report, leveraging over 200 user interviews, shines a light on ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton ... for pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in ... manufacturers step up to semi-automatic or fully-automatic case packing with a small footprint, ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Bluestar Silicones ... (LSR) product line for long-term implant applications and ... Medical Design & Manufacturing (MD&M) West Conference (Booth ... --> --> ... Silbione® Biomedical LSRs offer outstanding physical properties enabling ...
(Date:2/8/2016)... , Feb.8, 2016 Respiratory Devices - ... GlobalData,s Medical Devices sector report, " Respiratory Devices ... an overview of Respiratory Devices currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG Technologies, ... PW Series Solvent Recycling Systems, specifically designed for ... integration with new and existing vapor degreasers, parts ... consistently-fresh solvent through continuous recycling and recovers 100% ... --> --> Precision parts manufacturers ...
Breaking Medicine Technology: